Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival.
about
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.Bayesian enrichment strategies for randomized discontinuation trialsPhase II clinical trials in oncology: are we hitting the target?Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design.Optimal Bayesian enrichment: a view from the closet.Purified dry extract of Paullinia cupana (guaraná) (PC-18) for chemotherapy-related fatigue in patients with solid tumors: an early discontinuation study.
P2860
Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of power between ra ...... on progression-free survival.
@en
Comparison of power between ra ...... on progression-free survival.
@nl
type
label
Comparison of power between ra ...... on progression-free survival.
@en
Comparison of power between ra ...... on progression-free survival.
@nl
prefLabel
Comparison of power between ra ...... on progression-free survival.
@en
Comparison of power between ra ...... on progression-free survival.
@nl
P2860
P356
P1476
Comparison of power between ra ...... n on progression-free survival
@en
P2093
Afshin Dowlati
Mark Schluchter
P2860
P304
P356
10.1200/JCO.2008.19.6709
P407
P50
P577
2009-07-27T00:00:00Z